I understand the way you’re feeling and am equally disappointed...

I understand the way you’re feeling and am equally disappointed in the lack of progress (the kind that translates into revenue now). Before buying in at what now seems a crazy high price, I thought that with a unique, better and less expensive product, plus a great board and management, Osteopore had all the right ingredients for fast success.

To temper my disappointment and maybe yours too, I would say that Osteopore is making progress – just not the kind I mentioned above. Also, it was my fault for buying at $1 when it was clear that hype and FOMO were the key drivers of the share price post-listing, not any actual results. A lesson learned. Wait.

Based on its balance sheet only, the company is really not worth any more than the market is currently pricing it at. But with some real runs on the board like actual contracts for supply, OSX can still deliver the kind of share price we thought it would. But I agree they need to move fast to justify staying in.